| Drug Name |
Ramucirumab |
| Drug ID |
BADD_D01911 |
| Description |
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. |
| Indications and Usage |
For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. |
| Marketing Status |
Prescription |
| ATC Code |
L01FG02 |
| DrugBank ID |
DB05578
|
| KEGG ID |
D09371
|
| MeSH ID |
C543333
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D09HVD
|
| NDC Product Code |
63419-0535; 0002-7669; 73424-0329; 0002-2129; 0002-7678; 0002-2477 |
| Synonyms |
ramucirumab | LY3009806 | Cyramza | IMC 1121B | IMC1121B | IMC-1121B | 1121B |
